Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy

A. H. Rajput, R. J. Uitti, M. E. Fenton, D. George

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) each respond poorly to most anti-parkinsonian drugs. We assessed PSP and MSA cases seen between 1970 and 1996 for response to amantadine (Amd) 100 mg twice daily. Of 13 MSA cases (six females, seven males), eight (61.5%) improved, four (30.8%) did not benefit and one had insufficient documentation. Adverse effects were observed in three (23.1%) cases. Of 14 PSP (three females, 11 males), six (42.9%) had some improvement, five (35.7%) had no benefit, and three (21.4%) had inadequate documentation. Adverse effects were noted in three (28.6%) cases. Improvement is likely related to NMDA antagonist properties of Amd. We recommend consideration of Amd in the management of both PSP and MSA.

Original languageEnglish (US)
Pages (from-to)211-214
Number of pages4
JournalParkinsonism and Related Disorders
Volume3
Issue number4
DOIs
StatePublished - Dec 1998

Fingerprint

Progressive Supranuclear Palsy
Multiple System Atrophy
Amantadine
Documentation
N-Methylaspartate
Pharmaceutical Preparations

Keywords

  • Amantadine
  • Multiple system atrophy
  • Progressive supranuclear palsy

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Neurology

Cite this

Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. / Rajput, A. H.; Uitti, R. J.; Fenton, M. E.; George, D.

In: Parkinsonism and Related Disorders, Vol. 3, No. 4, 12.1998, p. 211-214.

Research output: Contribution to journalArticle

Rajput, A. H. ; Uitti, R. J. ; Fenton, M. E. ; George, D. / Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. In: Parkinsonism and Related Disorders. 1998 ; Vol. 3, No. 4. pp. 211-214.
@article{e7154c552c1e42e29d78b53c1b2b4204,
title = "Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy",
abstract = "Progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) each respond poorly to most anti-parkinsonian drugs. We assessed PSP and MSA cases seen between 1970 and 1996 for response to amantadine (Amd) 100 mg twice daily. Of 13 MSA cases (six females, seven males), eight (61.5{\%}) improved, four (30.8{\%}) did not benefit and one had insufficient documentation. Adverse effects were observed in three (23.1{\%}) cases. Of 14 PSP (three females, 11 males), six (42.9{\%}) had some improvement, five (35.7{\%}) had no benefit, and three (21.4{\%}) had inadequate documentation. Adverse effects were noted in three (28.6{\%}) cases. Improvement is likely related to NMDA antagonist properties of Amd. We recommend consideration of Amd in the management of both PSP and MSA.",
keywords = "Amantadine, Multiple system atrophy, Progressive supranuclear palsy",
author = "Rajput, {A. H.} and Uitti, {R. J.} and Fenton, {M. E.} and D. George",
year = "1998",
month = "12",
doi = "10.1016/S1353-8020(97)00022-9",
language = "English (US)",
volume = "3",
pages = "211--214",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy

AU - Rajput, A. H.

AU - Uitti, R. J.

AU - Fenton, M. E.

AU - George, D.

PY - 1998/12

Y1 - 1998/12

N2 - Progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) each respond poorly to most anti-parkinsonian drugs. We assessed PSP and MSA cases seen between 1970 and 1996 for response to amantadine (Amd) 100 mg twice daily. Of 13 MSA cases (six females, seven males), eight (61.5%) improved, four (30.8%) did not benefit and one had insufficient documentation. Adverse effects were observed in three (23.1%) cases. Of 14 PSP (three females, 11 males), six (42.9%) had some improvement, five (35.7%) had no benefit, and three (21.4%) had inadequate documentation. Adverse effects were noted in three (28.6%) cases. Improvement is likely related to NMDA antagonist properties of Amd. We recommend consideration of Amd in the management of both PSP and MSA.

AB - Progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) each respond poorly to most anti-parkinsonian drugs. We assessed PSP and MSA cases seen between 1970 and 1996 for response to amantadine (Amd) 100 mg twice daily. Of 13 MSA cases (six females, seven males), eight (61.5%) improved, four (30.8%) did not benefit and one had insufficient documentation. Adverse effects were observed in three (23.1%) cases. Of 14 PSP (three females, 11 males), six (42.9%) had some improvement, five (35.7%) had no benefit, and three (21.4%) had inadequate documentation. Adverse effects were noted in three (28.6%) cases. Improvement is likely related to NMDA antagonist properties of Amd. We recommend consideration of Amd in the management of both PSP and MSA.

KW - Amantadine

KW - Multiple system atrophy

KW - Progressive supranuclear palsy

UR - http://www.scopus.com/inward/record.url?scp=0031447893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031447893&partnerID=8YFLogxK

U2 - 10.1016/S1353-8020(97)00022-9

DO - 10.1016/S1353-8020(97)00022-9

M3 - Article

C2 - 18591078

AN - SCOPUS:0031447893

VL - 3

SP - 211

EP - 214

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 4

ER -